News

This Phase I, randomized, double-blind, placebo-controlled trial will evaluate the safety, tolerability, pharmacokinetics and uric acid lowering effects of single ascending oral doses of RDEA594 in healthy adult

Net earnings for the first quarter of fiscal year 2009 were $747 million, or $0.66 per diluted share, an increase of 11% and 12%, respectively, over the same

In this role, Mr Gonze will oversee Averion’s global business development and marketing activities, and will serve on the company’s executive management team. For the past six years

The shares were purchased by certain private investors on August 19, 2008. The shares were sold in a company managed private investment in public equity transaction at a

Mr Sherlock replaces Gilbert Kampfner, who is retiring after almost nine years with the company. Mr Sherlock, who joined ISI as director of business development in 2007, has

Mr Tsolinas currently serves as chairman and CEO of TMA Group Development, a Chicago-based real estate, architectural and development firm. Mr Tsolinas has earned a BA degree in

This patent-pending kit contains proprietary reagents, consumable processing containers (Pulse Tubes), and instructions for use, and is intended to be used with the company’s patented pressure cycling technology

Enobia is investigating enzyme replacement therapy (ERT) with ENB-0040 for the treatment of this genetic bone disorder for which there is no approved treatment. Under two separate protocols,

Many protocols for inducing the development embryonic and induced pluripotent stem cells into clinically relevant cell types rely on the formation of embryoid bodies (EBs), which are three-dimensional